Despite the macroeconomic challenges that have beset the global life sciences sector, biotech firms in Switzerland together raised more than CHF1.3bn ($1.45bn) in 2022 according to the Swiss Biotech Association’s latest annual report. Around CHF780m of this was collected by public companies with the remaining CHF550m collected by privately held firms.
From Public Funds To VCs: Swiss Financing For Swiss Biotech
Innovation Grants And Mid-Stage Raises
While most of the cash for Swiss biotech firms comes from outside the country, around 20% is provided by Swiss entities. Scrip spoke with two of these home-grown supporters of life sciences innovation about the move from academia to industry and their respective investment strategies.
More from Financing
• By
CEO Kris Elverum told Scrip about the start-up’s platform for editing RNA to correct genetic variants that cause harm and to reproduce healthy variants as a means of treating disease.
• By
The four-year-old firm said it plans to advance programs toward the clinic from the funding round, which comes just over a year after signing two major pharma partnerships.
• By
Private Company Edition: The latest group of drug developers to announce venture capital financings is remarkable for its geographic diversity, from Character Biosciences’ $93m series B round in the US to Augustine’s $85m series B in Belgium to a $29.2m series C for Aculys in Japan.
• By
Kyoto-based venture moves HQ to California to expand R&D and business outreach for its regulatory T-cell technology, as it raises around $46m in public and private funding.
More from Business
• By
Trump announced a 26% reciprocal tariff on India but a country-agnostic exemption of pharmaceuticals implies that the interests of Indian firms and the US consumer are protected for now. What is Indian pharma’s business exposure and what is domestic industry saying?
• By
Industry lobbied for pharmaceuticals to be exempt from Trump’s sweeping US tariffs and the effort appears to have paid off. J&J, Lilly and Merck & Co. even got shout outs.
• By
With new Phase II data, Edgewise asserted that EDG-7500, a sarcomere modulator, could offer better efficacy and safety than cardiac myosin inhibitors in hypertrophic cardiomyopathy.